Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models

Pharmacological Reviews

Volumn 61, Issue 3, 2009, Pages 262-282

  Deng, Xiaomin ^a   Luyendyk, James P ^c   Ganey, Patricia E ^b   Roth, Robert A ^b  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; BILIRUBIN; CHLORPROMAZINE; DICLOFENAC; DRUG METABOLITE; FAMOTIDINE; GAMMA GLUTAMYLTRANSFERASE; HALOTHANE; LEVOFLOXACIN; RANITIDINE; SULINDAC; TROGLITAZONE; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COMORBIDITY; CYTOKINE RELEASE; HEMOSTASIS; HISTOPATHOLOGY; HUMAN; IDIOSYNCRATIC LIVER TOXICITY; IMMUNITY; INFLAMMATION; LIVER ISCHEMIA; LIVER TOXICITY; MOLECULAR INTERACTION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; TISSUE INJURY; VIRUS HEPATITIS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL;

EID: 70349694415     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.109.001727     Document Type: Article

References (268)

1. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, and Harkins RN (1985) Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260:2345-2354. (Pubitemid 15104839)
2. Aithal GP and Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563-575, vi-vii.
3. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, Caldwell J, and Day CP (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430-1440. (Pubitemid 38569066)
4. Amar PJ and Schiff ER (2007) Acetaminophen safety and hepatotoxicity - where do we go from here? Expert Opin Drug Saf 6:341-355.
5. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, et al. (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129:512-521.
6. Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y, Pachkoria K, García-Cortés M, Fernández MC, Pelaez G, Rodrigo L, et al. (2006) Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44:1581-1588. (Pubitemid 44953663)
7. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, et al. (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133:263-274. (Pubitemid 30660298)
8. Arteel GE (2008) New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol 23 (Suppl 1):S54-S59.
9. Atchison CR, West AB, Balakumaran A, Hargus SJ, Pohl LR, Daiker DH, Aronson JF, Hoffmann WE, Shipp BK, and Treinen-Moslen M (2000) Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 119:1537-1547. (Pubitemid 32198679)
10. Bagheri H, Michel F, Lapeyre-Mestre M, Lagier E, Cambus JP, Valdiguié P, and Montastruc JL (2000) Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 50:479-484. (Pubitemid 30846021)
11. Banfi C, Sironi L, De Simoni G, Gelosa P, Barcella S, Perego C, Gianazza E, Guerrini U, Tremoli E, and Mussoni L (2004) Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats. J Pharmacol Exp Ther 310:890-895. (Pubitemid 39108908)
12. Banks AT, Zimmerman HJ, Ishak KG, and Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22:820-827.
13. Barr GD and Piper DW (1981) Possible ranitidine hepatitis. Med J Aust 2:421.
14. Barton CC, Barton EX, Ganey PE, Kunkel SL, and Roth RA (2001) Bacterial lipopolysaccharide enhances aflatoxin B1 hepatotoxicity in rats by a mechanism that depends on tumor necrosis factor α. Hepatology 33:66-73.
15. Barton CC, Ganey PE, and Roth RA (2000) Lipopolysaccharide augments aflatoxin B(1)-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol Sci 58:208-215. (Pubitemid 30815893)
16. Beier JI, Luyendyk JP, Guo L, von Montfort C, Staunton DE, and Arteel GE (2009) Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology 49:1545-1553.
17. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, and Arteel GE (2006) Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 130:2099-2112. (Pubitemid 43816952)
18. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, Luther T, Müller M, Böhrer H, and Greten J (1995) Mechanism of the tumor necrosis factor α-mediated induction of endothelial tissue factor. J Biol Chem 270:26419-26432.
19. Black M, Scott WE Jr, and Kanter R (1984) Possible ranitidine hepatotoxicity. Ann Intern Med 101:208-210.
20. Bober LA, Waters TA, Pugliese-Sivo CC, Sullivan LM, Narula SK, and Grace MJ (1995) IL-4 induces neutrophilic maturation of HL-60 cells and activation of human peripheral blood neutrophils. Clin Exp Immunol 99:129-136.
21. Boelsterli UA (2003a) Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity. Curr Opin Drug Discov Devel 6:81-91.
22. Boelsterli UA (2003b) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322.
23. Boelsterli UA and Hsiao CJ (2008) The heterozygous Sod2(+/-) mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 13:982-988.
24. Bonkovsky HL, Azar R, Bird S, Szabo G, and Banner B (2002) Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 47:1632-1637. (Pubitemid 34753947)
25. Bort R, Ponsoda X, Jover R, Gómez-Lechón MJ, and Castell JV (1999) Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 288:65-72. (Pubitemid 29113474)
26. Bradham CA, Plümpe J, Manns MP, Brenner DA, and Trautwein C (1998) Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 275:G387-G392. (Pubitemid 28439710)
27. Bredfeldt JE and von Huene C (1984) Ranitidine, acetaminophen, and hepatotoxicity. Ann Intern Med 101:719.
28. Brown AP, Harkema JR, Schultze AE, Roth RA, and Ganey PE (1997) Gadolinium chloride pretreatment protects against hepatic injury but predisposes the lungs to alveolitis after lipopolysaccharide administration. Shock 7:186-192.
29. Buchweitz JP, Ganey PE, Bursian SJ, and Roth RA (2002) Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300:460-467.
30. Butcher EC (1991) Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033-1036.
31. Cantoni L, Valaperta R, Ponsoda X, Castell JV, Barelli D, Rizzardini M, Mangolini A, Hauri L, and Villa P (2003) Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity. J Hepatol 38:776-783. (Pubitemid 36613344)
32. Carey PF, Martin LE, and Owen PE (1981) Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr 225:161-168. (Pubitemid 12198773)
33. Carini R, de Cesaris MG, Bellomo G, and Albano E (1997) Role of Na+/Ca2+ exchanger in preventing Na+ overload and hepatocyte injury: opposite effects of extracellular and intracellular Ca2+ chelation. Biochem Biophys Res Commun 232:107-110.
34. Carini R, De Cesaris MG, Splendore R, Bagnati M, and Albano E (2000) Ischemic preconditioning reduces Na(+) accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia. Hepatology 31:166-172. (Pubitemid 30033703)
35. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J, and Drug Induced Liver Injury Network (DILIN) (2008) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135:1924-1934.
36. Cheng L, You Q, Yin H, Holt M, Franklin C, and Ju C (2009) Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 49:215-226.
37. Chojkier M (2005) Troglitazone and liver injury: in search of answers. Hepatology 41:237-246.
38. Chung WG, Park CS, Roh HK, Lee WK, and Cha YN (2000) Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol 84:213-220.
39. Cohen A and Fabre L (1983) Tolerance to repeated intravenous doses of ranitidine HCl and cimetidine HCl in normal volunteers. Curr Ther Res 43:475-482. (Pubitemid 14231543)
40. Colin-Jones DG, Ireland A, Gear P, Golding PL, Ramage JK, Williams JG, Leicester RJ, Smith CL, Ross G, and Bamforth J (1984) Reducing overnight secretion of acid to heal duodenal ulcers. Comparison of standard divided dose of ranitidine with a single dose administered at night. Am J Med 77:116-122. (Pubitemid 15175994)
41. Copple BL, Moulin F, Hanumegowda UM, Ganey PE, and Roth RA (2003) Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide- induced hepatocellular injury in perfused livers. J Pharmacol Exp Ther 305:417-425. (Pubitemid 36459153)
42. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, and Schauer PR (2004) The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 14:589-600. (Pubitemid 38716577)
43. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, and Day CP (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272-281.
44. de la Iglesia FA, Haskins JR, and Feuer G (2003) Hepatotoxicity of cardiovascular and antidiabetic drugs, in Drug-Induced Liver Disease (Kaplowitz N, DeLeve LD eds) pp 549-552, Marcel Dekker, New York.
45. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, and Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269.
46. Deng X, Liguori MJ, Sparkenbaugh EM, Waring JF, Blomme EA, Ganey PE, and Roth RA (2008) Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury. J Pharmacol Exp Ther 327:634-644.
47. Deng X, Luyendyk JP, Zou W, Lu J, Malle E, Ganey PE, and Roth RA (2007) Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 322:852-861.
48. Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, and Roth RA (2006) Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319:1191-1199. (Pubitemid 44776466)
49. Desaint B, Alperine M, Legendre C, Florent C, and Levy VG (1985) [Hepatitis Caused by Ranitidine]. Gastroenterol Clin Biol 9:746-747.
50. Devuyst O, Lefebvre C, Geubel A, and Coche E (1993) Acute cholestatic hepatitis with rash and hypereosinophilia associated with ranitidine treatment. Acta Clin Belg 48:109-114. (Pubitemid 23189274)
51. Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J, Kasdan P, Ahlers CM, and Ecto LT (1993) Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 6:787-794.
52. Dieckhaus CM, Thompson CD, Roller SG, and Macdonald TL (2002) Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 142:99-117. (Pubitemid 35232556)
53. Dugan CM, Roth RA, and Ganey PE (2008) Determinants of sensitivity to halothane-induced hepatotoxicity in mice (Abstract). Toxicol Sci 102 (Suppl):174.
54. Echtenacher B, Falk W, Männel DN, and Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145:3762-3766.
55. Echtenacher B, Hültner L, and Männel DN (1995) Cellular and molecular mechanisms of TNF protection in septic peritonitis. J Inflamm 47:85-89. (Pubitemid 26376206)
56. Echtenacher B and Männel DN (2002) Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis. J Endotoxin Res 8:365-369. (Pubitemid 35460671)
57. Echtenacher B, Urbaschek R, Weigl K, Freudenberg MA, and Männel DN (2003) Treatment of experimental sepsis-induced immunoparalysis with TNF. Immunobiology 208:381-389. (Pubitemid 38081361)
58. Eichelbaum M and Burk O (2001) CYP3A genetics in drug metabolism. Nat Med 7:285-287.
59. Fan J, Kapus A, Li YH, Rizoli S, Marshall JC, and Rotstein OD (2000) Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am J Respir Cell Mol Biol 22:412-421. (Pubitemid 30343340)
60. Fink T, Kazlauskas A, Poellinger L, Ebbesen P, and Zachar V (2002) Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 99:2077-2083. (Pubitemid 34525491)
61. Flick MJ, Du X, and Degen JL (2004a) Fibrin(ogen)-α M β 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood) 229:1105-1110. (Pubitemid 39602252)
62. Flick MJ, Du X, Witte DP, Jirousková M, Soloviev DA, Busuttil SJ, Plow EF, and Degen JL (2004b) Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 113:1596-1606. (Pubitemid 39071683)
63. Ganey PE, Bailie MB, VanCise S, Colligan ME, Madhukar BV, Robinson JP, and Roth RA (1994) Activated neutrophils from rat injured isolated hepatocytes. Lab Invest 70:53-60. (Pubitemid 24080104)
64. Ganey PE, Barton YW, Kinser S, Sneed RA, Barton CC, and Roth RA (2001) Involvement of cyclooxygenase-2 in the potentiation of allyl alcohol-induced liver injury by bacterial lipopolysaccharide. Toxicol Appl Pharmacol 174:113-121. (Pubitemid 32675513)
65. Ganey PE, Luyendyk JP, Maddox JF, and Roth RA (2004) Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 150:35-51.
66. Ganey PE and Roth RA (2001) Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology 169:195-208.
67. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, and Rowlands BJ (1995) Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36:897-901.
68. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, and Gordon JL (1994) Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370:555-557. (Pubitemid 24264920)
69. Goel MS and Diamond SL (2003) Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets. J Biol Chem 278:9458-9463.
70. Goel MS and Diamond SL (2004) Factor VIIa-mediated tenase function on activated platelets under flow. J Thromb Haemost 2:1402-1410.
71. Gómez-Lechón MJ, Ponsoda X, O'Connor E, Donato T, Jover R, and Castell JV (2003) Diclofenac induces apoptosis in hepatocytes. Toxicol In Vitro 17:675-680.
72. Graham DJ, Green L, Senior JR, and Nourjah P (2003) Troglitazone-induced liver failure: a case study. Am J Med 114:299-306. (Pubitemid 36398076)
73. Graham DY, Opekun AR, Smith JL, and Schwartz JT (1985) Ranitidine and hepatotoxicity. Ann Intern Med 102:416.
74. Greaves RR, Agarwal A, Patch D, Davies SE, Sherman D, Reynolds N, Rolles K, Davidson BR, and Burroughs AK (2001) Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur J Gastroenterol Hepatol 13:71-73. (Pubitemid 32099573)
75. Guha M and Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85-94. (Pubitemid 32222977)
76. Gujral JS, Hinson JA, Farhood A, and Jaeschke H (2004) NADPH oxidase-derived oxidant stress is critical for neutrophil cytotoxicity during endotoxemia. Am J Physiol Gastrointest Liver Physiol 287:G243-G252. (Pubitemid 38802139)
77. Gutting BW, Bouzahzah F, Kong PL, Updyke LW, Amacher DE, and Craft J (2003) Oxazolone and diclofenac-induced popliteal lymph node assay reactions are attenuated in mice orally pretreated with the respective compound: potential role for the induction of regulatory mechanisms following enteric administration. Toxicol Appl Pharmacol 189:120-133. (Pubitemid 36638280)
78. Gutting BW, Updyke LW, and Amacher DE (2002) Diclofenac activates T cells in the direct popliteal lymph node assay and selectively induces IgG(1) and IgE against co-injected TNP-OVA. Toxicol Lett 131:167-180.
79. Halparin LS (1984) Adverse effects of ranitidine therapy. Can Med Assoc J 130:668-672.
80. Harbrecht BG, Billiar TR, Curran RD, Stadler J, and Simmons RL (1993) Hepatocyte injury by activated neutrophils in vitro is mediated by proteases. Ann Surg 218:120-128. (Pubitemid 23229137)
81. Hasegawa T, Malle E, Farhood A, and Jaeschke H (2005) Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioning. Am J Physiol Gastrointest Liver Physiol 289:G760-G767. (Pubitemid 41377184)
82. He K, Talaat RE, Pool WF, Reily MD, Reed JE, Bridges AJ, and Woolf TF (2004) Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos 32:639-646. (Pubitemid 38668157)
83. Hehlgans T and Pfeffer K (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115:1-20. (Pubitemid 40598088)
84. Hekman CM and Loskutoff DJ (1985) Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581-11587.
85. Hewett JA and Roth RA (1993) Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Pharmacol Rev 45:382-411.
86. Hewett JA and Roth RA (1995) The coagulation system, but not circulating fibrinogen, contributes to liver injury in rats exposed to lipopolysaccharide from gram-negative bacteria. J Pharmacol Exp Ther 272:53-62.
87. Hewett JA, Schultze AE, VanCise S, and Roth RA (1992) Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Invest 66:347-361.
88. Hiesse C, Cantarovich M, Santelli C, Francais P, Charpentier B, Fries D, and Buffet C (1985) Ranitidine hepatotoxicity in renal transplant patient. Lancet 1:1280. (Pubitemid 15036503)
89. Hirschowitz BI, Berenson MM, Berkowitz JM, Bright-Asare P, DeLuca VA Jr, Eshelman FN, Font RG, Griffin JW Jr, Kozarek RA, and McCray RS (1986) A multicenter study of ranitidine treatment of duodenal ulcers in the United States. J Clin Gastroenterol 8:359-366. (Pubitemid 16054903)
90. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, and Gaestel M (2006) Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 26:2399-2407. (Pubitemid 43346938)
91. Ho JS, Buchweitz JP, Roth RA, and Ganey PE (1996) Identification of factors from rat neutrophils responsible for cytotoxicity to isolated hepatocytes. J Leukoc Biol 59:716-724. (Pubitemid 26198083)
92. Hoekstra T, Geleijnse JM, Schouten EG, and Kluft C (2004) Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91:861-872. (Pubitemid 38647488)
93. Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, Ikeda T, and Yamazoe Y (2002) Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949. (Pubitemid 34815426)
94. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, and Vaughan DE (2004) Tumor necrosis factor α activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor κB site. J Biol Chem 279:18127-18136. (Pubitemid 38623225)
95. Huang SM, Tsai TR, Yeh PH, and Tsai TH (2005) Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. J Chromatogr A 1073:297-302. (Pubitemid 40544502)
96. Hussaini SH and Farrington EA (2007) Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 6:673-684. (Pubitemid 351308279)
97. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
98. Jaeschke H, Farhood A, and Smith CW (1990) Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J 4:3355-3359. (Pubitemid 120012584)
99. Jaeschke H, Farhood A, and Smith CW (1991) Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism. Am J Physiol 261:G1051-G1056.
100. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, and Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicol Sci 65:166-176.
101. Jaeschke H, Ho YS, Fisher MA, Lawson JA, and Farhood A (1999) Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Hepatology 29:443-450. (Pubitemid 29088448)
102. Jaeschke H, Smith CW, Clemens MG, Ganey PE, and Roth RA (1996) Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol 139:213-226. (Pubitemid 26281597)
103. Jones DB, Hanson RG, Mihaly GW, Johnson RD, Louis WJ, Yeomans ND, and Smallwood RA (1982) Double-blind controlled trial of ranitidine versus cimetidine in the treatment of duodenal ulceration. Aust N Z J Med 12:547-549. (Pubitemid 13141542)
104. Ju C and Uetrecht JP (2002) Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 3:367-377. (Pubitemid 34778003)
105. Kantarçeken B, Cetinkaya A, Bülbüloǧlu E, Yerhan H, and Uçar MA (2006) Severe liver enzyme elevation due to single-dose ranitidine in a pregnant woman. Turk J Gastroenterol 17:242-243.
106. Kaplowitz N (2001) Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 24:483-490.
107. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
108. Karachalios GN (1985) Ranitidine and hepatitis. Ann Intern Med 103:634-635.
109. Kawabata K, Hagio T, and Matsuoka S (2002) The role of neutrophil elastase in acute lung injury. Eur J Pharmacol 451:1-10. (Pubitemid 35251839)
110. Kawai K, Kawasaki-Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T, Yoshioka T, et al. (1997) Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47:356-368. (Pubitemid 27207306)
111. Kim JW, Jeon WK, and Kim EJ (2005) Combined effects of bovine colostrum and glutamine in diclofenac-induced bacterial translocation in rat. Clin Nutr 24:785-793.
112. Kimura Y and Yokoi-Hayashi K (1996) Polymorphonuclear leukocyte lysosomal proteases, cathepsins B and D affect the fibrinolytic system in human umbilical vein endothelial cells. Biochim Biophys Acta 1310:1-4. (Pubitemid 26027259)
113. Kinser S, Copple BL, Roth RA, and Ganey PE (2002) Enhancement of allyl alcohol hepatotoxicity by endotoxin requires extrahepatic factors. Toxicol Sci 69:470-481. (Pubitemid 35244221)
114. Kinser S, Sneed R, Roth R, and Ganey P (2004) Neutrophils contribute to endotoxin enhancement of allyl alcohol hepatotoxicity. J Toxicol Environ Health A 67:911-928. (Pubitemid 38746354)
115. Kobayashi Y (2008) The role of chemokines in neutrophil biology. Front Biosci 13:2400-2407.
116. Kohlroser J, Mathai J, Reichheld J, Banner BF, and Bonkovsky HL (2000) Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272-276. (Pubitemid 30041572)
117. Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA, and Vogel SN (1999) Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 163:1537-1544. (Pubitemid 29352777)
118. Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, Galchev V, Rose K, Sinz M, and Strom SC (2000) The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 28:1192-1197. (Pubitemid 30747328)
119. Kretz-Rommel A and Boelsterli UA (1995) Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 22:213-222.
120. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. (Pubitemid 32268418)
121. Kushimoto S, Okajima K, Uchiba M, Murakami K, Harada N, Okabe H, and Takatsuki K (1996) Role of granulocyte elastase in ischemia/reperfusion injury of rat liver. Crit Care Med 24:1908-1912. (Pubitemid 26382937)
122. Küsters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Künstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, et al. (1997) In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27:2870-2875. (Pubitemid 27478356)
123. Kwak SH, Wang XQ, He Q, Fang WF, Mitra S, Bdeir K, Ploplis VA, Xu Z, Idell S, Cines D, et al. (2006) Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb Haemost 95:829-835.
124. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, Shakil AO, et al. (2005) Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42:1364-1372. (Pubitemid 43260039)
125. Laurens M, Defamie V, Scozzari G, Schmid-Alliana A, Gugenheim J, and Crenesse D (2005) Hypoxia-reoxygenation-induced chemokine transcription is not prevented by preconditioning or intermittent hypoxia, in mice hepatocytes. Transpl Int 18:444-452. (Pubitemid 41741802)
126. Lauritsen K, Havelund T, and Rask-Madsen J (1984) Ranitidine and hepatotoxicity. Lancet 2:1471.
127. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205. (Pubitemid 28193431)
128. Lee FI, Reed PI, Crowe JP, McIsaac RL, and Wood JR (1986) Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night. Gut 27:1091-1095. (Pubitemid 16053542)
129. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, and Edwards MJ (1998) Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 27:1172-1177. (Pubitemid 28081066)
130. Lepper PM, Held TK, Schneider EM, Bölke E, Gerlach H, and Trautmann M (2002) Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 28:824-833. (Pubitemid 34762215)
131. Levi M (2005) Disseminated intravascular coagulation: what's new? Crit Care Clin 21:449-467. (Pubitemid 40898154)
132. Levi M, Keller TT, van Gorp E, and ten Cate H (2003) Infection and inflammation and the coagulation system. Cardiovasc Res 60:26-39.
133. Lewis JH (2003) Nonsteroidal anti-inflammatory drugs: pathology and clinical presentation of hepatotoxicity, in Drug-Induced Liver Disease (Kaplowitz N, DeLeve LD eds) pp 377-404, Marcel Dekker, New York.
134. Ley K, Laudanna C, Cybulsky MI, and Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678-689. (Pubitemid 47327397)
135. Li AP (2002) A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142:7-23.
136. Li X, Klintman D, Liu Q, Sato T, Jeppsson B, and Thorlacius H (2004) Critical role of CXC chemokines in endotoxemic liver injury in mice. J Leukoc Biol 75:443-452. (Pubitemid 38316375)
137. Liberopoulos EN, Nonni AB, Tsianos EV, and Elisaf MS (2002) Possible ranitidine-induced cholestatic jaundice. Ann Pharmacother 36:172.
138. Lim MS, Lim PL, Gupta R, and Boelsterli UA (2006) Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol Appl Pharmacol 217:322-331. (Pubitemid 44855823)
139. Lim PL, Liu J, Go ML, and Boelsterli UA (2008) The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 101:341-349.
140. Lluis JM, Buricchi F, Chiarugi P, Morales A, and Fernandez-Checa JC (2007) Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{κ}B via c-SRC and oxidant-dependent cell death. Cancer Res 67:7368-7377. (Pubitemid 47206567)
141. Lluis JM, Morales A, Blasco C, Colell A, Mari M, Garcia-Ruiz C, and Fernandez-Checa JC (2005) Critical role of mitochondrial glutathione in the survival of hepatocytes during hypoxia. J Biol Chem 280:3224-3232. (Pubitemid 40223784)
142. Loi CM, Young M, Randinitis E, Vassos A, and Koup JR (1999) Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104.
143. Lu J, Roth RA, and Ganey PE (2009) Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats (Abstract). Toxicol Sci, in press.
144. Luo G, Garner CE, Xiong H, Hu H, Richards LE, Brouwer KL, Duan J, Decicco CP, Maduskuie T, Shen H, et al. (2007) Effect of DPC 333 [(2R)-2-{(3R)-3-amino- 3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl} -N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study. Drug Metab Dispos 35:835-840. (Pubitemid 46798593)
145. Luparini RL, Rotundo A, Mattace R, and Marigliano V (2000) [Possibly ranitidine-induced autoimmune hepatitis]. Ann Ital Med Int 15:214-217.
146. Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Deng X, Maddox JF, Ganey PE, et al. (2006a) Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J Pharmacol Exp Ther 317:635-643.
147. Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Maddox JF, Ganey PE, and Roth RA (2006b) Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine. Toxicol Sci 90:569-585.
148. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, and Roth RA (2003) Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 307:9-16.
149. Luyendyk JP, Maddox JF, Green CD, Ganey PE, and Roth RA (2004) Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide- ranitidine coexposure in rats. Hepatology 40:1342-1351.
150. Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, and Roth RA (2005) Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 314:1023-1031.
151. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, Voegele-Kadletz M, Huber-Beckmann R, Ullrich R, Binder BR, et al. (2002) Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1[α], tumor necrosis factor-[α], transforming growth factor-[β] and oncostatin m in human cardiac myocytes. J Mol Cell Cardiol 34:1681-1691. (Pubitemid 35454482)
152. Mackman N, Tilley RE, and Key NS (2007) Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 27:1687-1693. (Pubitemid 47207163)
153. Maher JJ, Scott MK, Saito JM, and Burton MC (1997) Adenovirus-mediated expression of cytokine-induced neutrophil chemoattractant in rat liver induces a neutrophilic hepatitis. Hepatology 25:624-630.
154. Masubuchi Y (2006) Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347-356.
155. Masubuchi Y, Nakayama S, and Horie T (2002) Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35:544-551. (Pubitemid 34183957)
156. Maugeri N, Brambilla M, Camera M, Carbone A, Tremoli E, Donati MB, de Gaetano G, and Cerletti C (2006) Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 4:1323-1330. (Pubitemid 43756712)
157. Mavier P, Preaux AM, Guigui B, Lescs MC, Zafrani ES, and Dhumeaux D (1988) In vitro toxicity of polymorphonuclear neutrophils to rat hepatocytes: evidence for a proteinase-mediated mechanism. Hepatology 8:254-258. (Pubitemid 18134250)
158. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, and Kidao S (1994) Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370:558-561. (Pubitemid 24264921)
159. Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, and Mergenhagen SE (1980) The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 141:55-63.
160. Miyamoto G, Zahid N, and Uetrecht JP (1997) Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol 10:414-419. (Pubitemid 27176303)
161. Mizoguchi Y, Shin T, Mizuno M, Seki S, Kobayashi K, and Morisawa S (1990) The enhancement of liver injury by lipopolysaccharide in an experimental drug-induced allergic hepatitis model. Gastroenterol Jpn 25:458-462. (Pubitemid 20277692)
162. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, and Weerawarna K (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218-220. (Pubitemid 24236777)
163. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216. (Pubitemid 351185732)
164. Moulin F, Copple BL, Ganey PE, and Roth RA (2001) Hepatic and extrahepatic factors critical for liver injury during lipopolysaccharide exposure. Am J Physiol Gastrointest Liver Physiol 281:G1423-G1431. (Pubitemid 33775093)
165. Müllberg J, Althoff K, Jostock T, and Rose-John S (2000) The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 11:27-38. (Pubitemid 30145399)
166. Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, Freise C, Lee WM, and Bass NM (2000) Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 45:549-553.
167. Nagaki M, Muto Y, Ohnishi H, and Moriwaki H (1991) Significance of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in the pathogenesis of fulminant hepatitis: possible involvement of serine protease in TNF-mediated liver injury. Gastroenterol Jpn 26:448-455.
168. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, Volk HD, Holtmann H, Kollias G, and Gaestel M (2002) MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem 277:3065-3068. (Pubitemid 34953164)
169. Numahata K, Komagata T, Hirasawa N, Someya K, Xiao YQ, and Ohuchi K (2003) Analysis of the mechanism regulating the stability of rat macrophage inflammatory protein-2 MRNA in RBL-2H3 Cells. J Cell Biochem 90:976-986. (Pubitemid 37467113)
170. Oda K and Kitano H (2006) A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2:2006.0015. (Pubitemid 43948158)
171. Offit K and Sojka DA (1984) Ranitidine (Letter). N Engl J Med 310:1603-1604.
172. Okajima K, Harada N, and Uchiba M (2002) Ranitidine reduces ischemia/reperfusion-induced liver injury in rats by inhibiting neutrophil activation. J Pharmacol Exp Ther 301:1157-1165. (Pubitemid 34595110)
173. Okajima K, Murakami K, Liu W, and Uchiba M (2000) Inhibition of neutrophil activation by ranitidine contributes to prevent stress-induced gastric mucosal injury in rats. Crit Care Med 28:2858-2865. (Pubitemid 30676535)
174. Ong MM, Latchoumycandane C, and Boelsterli UA (2007) Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97:205-213. (Pubitemid 47072169)
175. Owensby DA, Morton PA, Wun TC, and Schwartz AL (1991) Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem 266:4334-4340.
176. Padró T, Emeis JJ, Steins M, Schmid KW, and Kienast J (1995) Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 15:893-902.
177. Padró T, Steins M, Li CX, Mesters RM, Hammel D, Scheld HH, and Kienast J (1997) Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc Res 36:28-36. (Pubitemid 27463569)
178. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, and Pirmohamed M (2001) Metabolic activation in drug allergies. Toxicology 158:11-23.
179. Parry GC and Mackman N (1995) Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 15:612-621.
180. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, and Mackman N (2004) Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 103:1342-1347. (Pubitemid 38168646)
181. Pearson JM, Brown AP, Schultze AE, Ganey PE, and Roth RA (1996a) Gadolinium chloride treatment attenuates hepatic platelet accumulation after lipopolysaccharide administration. Shock 5:408-415.
182. Pearson JM, Schultze AE, Schwartz KA, Scott MA, Davis JM, and Roth RA (1996b) The thrombin inhibitor, hirudin, attenuates lipopolysaccharide-induced liver injury in the rat. J Pharmacol Exp Ther 278:378-383. (Pubitemid 27167117)
183. Pellock JM (1999) Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 21:225-239.
184. Petrovic V, Teng S, and Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111. (Pubitemid 46683180)
185. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, and Mak TW (1993) Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467. (Pubitemid 23143346)
186. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, Johnson RC, Hynes RO, Heath M, Lawson CA, et al. (1996) Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 97:493-500. (Pubitemid 26039415)
187. Pintucci G, Iacoviello L, Amore C, Evangelista V, Cerletti C, and Donati MB (1992) Cathepsin G, a polymorphonuclear cell protease, affects the fibrinolytic system by releasing PAI-1 from endothelial cells and platelets. Ann N Y Acad Sci 667:286-288. (Pubitemid 23061594)
188. Pintucci G, Iacoviello L, Castelli MP, Amore C, Evangelista V, Cerletti C, and Donati MB (1993) Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells: a new thrombogenic role for polymorphonuclear leukocytes? J Lab Clin Med 122:69-79. (Pubitemid 23206876)
189. Piret JP, Mottet D, Raes M, and Michiels C (2002) Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 64:889-892.
190. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, and Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19. (Pubitemid 38869995)
191. Pirmohamed M, Naisbitt DJ, Gordon F, and Park BK (2002) The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182:55-63. (Pubitemid 36015673)
192. Prendergast KA, Berg CL, and Wisniewski R (2000) Troglitazone-associated hepatotoxicity treated successfully with steroids. Ann Intern Med 133:751.
193. Proctor JD (1984) Hepatitis associated with ranitidine. JAMA 251:1554.
194. Ramrakhiani S, Brunt EM, and Bacon BR (1998) Possible cholestatic injury from ranitidine with a review of the literature. Am J Gastroenterol 93:822-826. (Pubitemid 29063930)
195. Rau JC, Beaulieu LM, Huntington JA, and Church FC (2007) Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5 (Suppl 1):102-115.
196. Renton KW (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629-640.
197. Ribeiro JM, Lucas M, Baptista A, and Victorino RM (2000) Fatal hepatitis associated with ranitidine. Am J Gastroenterol 95:559-560.
198. Rietschel ET, Brade H, Holst O, Brade L, Müller-Loennies S, Mamat U, Zähringer U, Beckmann F, Seydel U, Brandenburg K, et al. (1996) Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 216:39-81. (Pubitemid 28012915)
199. Roth RA, Harkema JR, Pestka JP, and Ganey PE (1997) Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol Appl Pharmacol 147:300-311.
200. Roth RA, Luyendyk JP, Maddox JF, and Ganey PE (2003) Inflammation and drug idiosyncrasy - is there a connection? J Pharmacol Exp Ther 307:1-8.
201. Rothwell C, McGuire EJ, Altrogge DM, Masuda H, and de la Iglesia FA (2002) Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci 27:35-47. (Pubitemid 34296681)
202. Scheen AJ (2001a) Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 24:873-888.
203. Scheen AJ (2001b) Thiazolidinediones and liver toxicity. Diabetes Metab 27:305-313.
204. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, and Loskutoff DJ (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797-5803. (Pubitemid 18122927)
205. Schleiffenbaum B and Fehr J (1990) The tumor necrosis factor receptor and human neutrophil function. Deactivation and cross-deactivation of tumor necrosis factor-induced neutrophil responses by receptor down-regulation. J Clin Invest 86:184-195. (Pubitemid 20226991)
206. Schümann J, Angermüller S, Bang R, Lohoff M, and Tiegs G (1998) Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J Immunol 161:5745-5754. (Pubitemid 28519143)
207. Schwabe RF and Brenner DA (2006) Mechanisms of liver injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 290:G583-G589.
208. Schwager I and Jungi TW (1994) Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 83:152-160. (Pubitemid 24016527)
209. Séguin B and Uetrecht J (2003) The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 3:235-242. (Pubitemid 37010877)
210. Seitz S and Boelsterli UA (1998) Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115:1476-1482. (Pubitemid 28545998)
211. Seitz S, Kretz-Rommel A, Oude Elferink RP, and Boelsterli UA (1998) Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11:513-519. (Pubitemid 28242496)
212. Senior JR (2008) What is idiosyncratic hepatotoxicity? What is it not? Hepatology 47:1813-1815.
213. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, and Hillon P (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451-455. (Pubitemid 34810366)
214. Shaw PJ, Ganey PE, and Roth RA (2009) Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive stimulus, resulting in neutrophil-dependent liver injury in mice. J Pharmacol Exp Ther 330:72-78.
215. Shaw PJ, Hopfensperger MJ, Ganey PE, and Roth RA (2007) Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-α. Toxicol Sci 100:259-266.
216. Shibayama Y (1987) Enhanced hepatotoxicity of endotoxin by hypoxia. Pathol Res Pract 182:390-395.
217. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, and Benjamin W (1992) Hypoxia-mediated induction of endothelial cell interleukin-1α. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333-2339. (Pubitemid 23010050)
218. Siu WP, Pun PB, Latchoumycandane C, and Boelsterli UA (2008) Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: multiple protective roles of cyclosporin A. Toxicol Appl Pharmacol 227:451-461.
219. Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB Jr, Henson PM, and Worthen GS (1986) Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 77:1233-1243.
220. Sneed RA, Grimes SD, Schultze AE, Brown AP, and Ganey PE (1997) Bacterial endotoxin enhances the hepatotoxicity of allyl alcohol. Toxicol Appl Pharmacol 144:77-87.
221. Soejima Y, Yanaga K, Nishizaki T, Yoshizumi T, Uchiyama H, and Sugimachi K (1999) Effect of specific neutrophil elastase inhibitor on ischemia/reperfusion injury in rat liver transplantation. J Surg Res 86:150-154. (Pubitemid 29418501)
222. Souza Lima MA (1984) Hepatitis associated with ranitidine. Ann Intern Med 101:207-208.
223. Spek CA (2004) Tissue factor: from 'just one of the coagulation factors' to a major player in physiology. Blood Coagul Fibrinolysis 15 (Suppl 1):S3-S10.
224. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314.
225. Tacke F, Luedde T, and Trautwein C (2009) Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 36:4-12.
226. Tafazoli S, Spehar DD, and O'Brien PJ (2005) Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab Rev 37:311-325. (Pubitemid 40677507)
227. Takei Y, Kawano S, Nishimura Y, Goto M, Nagai H, Chen SS, Omae A, Fusamoto H, Kamada T, Ikeda K, et al. (1995) Apoptosis: a new mechanism of endothelial and Kupffer cell killing. J Gastroenterol Hepatol 10 (Suppl 1):S65-S67.
228. Tamura DY, Moore EE, Partrick DA, Johnson JL, Offner PJ, and Silliman CC (2002) Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock 17:269-273.
229. Tartaglia LA, Rothe M, Hu YF, and Goeddel DV (1993) Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 73:213-216. (Pubitemid 23123300)
230. Tettey JN, Maggs JL, Rapeport WG, Pirmohamed M, and Park BK (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol 14:965-974. (Pubitemid 32800152)
231. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, Hart TK, Thomas HC, and Schwartz LW (2002) Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 69:131-138.
232. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3rd, Zentella A, and Albert JD (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474.
233. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, and Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664. (Pubitemid 18005583)
234. Tracy RP (2003) Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord 27 (Suppl 3):S29-S34.
235. Tukov FF, Luyendyk JP, Ganey PE, and Roth RA (2007) The role of tumor necrosis factor α in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 100:267-280. (Pubitemid 47617823)
236. Uetrecht J (1991) Metabolism of drugs by activated leukocytes: implications for drug-induced lupus and other drug hypersensitivity reactions. Adv Exp Med Biol 283:121-132.
237. Uetrecht J (2008) Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 21:84-92. (Pubitemid 351219710)
238. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513-539.
239. Valois M, Cooper MA, and Shear NH (2003) Clinical pharmacology consultations: consultation requests may be misleading - an organized approach to drug-induced hepatitis. Can J Clin Pharmacol 10:59-62. (Pubitemid 37028595)
240. van Bommel EF and Meyboom RH (1992) [Liver damage caused by ranitidine]. Ned Tijdschr Geneeskd 136:435-437.
241. Varriale M, Salvio A, Giannattasio F, d'Errico T, Montone L, Borgia F, Gentile I, Reynaud L, Borgia G, Rossiello R, et al. (2004) Intrahepatic cholestatic jaundice related to administration of ranitidine. A case report with histologic and ultramicroscopic study. Minerva Gastroenterol Dietol 50:339-343.
242. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452.
243. Vial T, Goubier C, Bergeret A, Cabrera F, Evreux JC, and Descotes J (1991) Side effects of ranitidine. Drug Saf 6:94-117.
244. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, and Monshouwer M (2005) An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216:154-167. (Pubitemid 41712005)
245. Vollmar B, Rüttinger D, Wanner GA, Leiderer R, and Menger MD (1996) Modulation of Kupffer cell activity by gadolinium chloride in endotoxemic rats. Shock 6:434-441. (Pubitemid 126727786)
246. Walker AM (1997) Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 40:201-208.
247. Waring JF and Anderson MG (2005) Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Devel 8:59-65.
248. Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, and Roth RA (2006) Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 316:1080-1087. (Pubitemid 43345281)
249. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, Takahashi T, Miyoshi K, Nakamura K, Izumi T, et al. (2003) A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73:435-455. (Pubitemid 36549828)
250. Watanabe Y, Nakajima M, and Yokoi T (2002) Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462-1469. (Pubitemid 35397055)
251. Watkins PB (2005) Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 33:1-5.
252. Watkins PB and Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917.
253. Westrick RJ and Eitzman DT (2007) Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets 8:966-1002.
254. Whitcomb DC (2004) Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer.. Am J Physiol Gastrointest Liver Physiol 287:G315-G319. (Pubitemid 38955250)
255. Willerson JT and Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109:II2-II10.
256. Williams DP and Park BK (2003) Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today 8:1044-1050.
257. Xu L, Xie K, Mukaida N, Matsushima K, and Fidler IJ (1999) Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 59:5822-5829.
258. Yamaguchi Y, Akizuki E, Ichiguchi O, Matsumura F, Goto M, Miyanari N, Mori K, Yamada S, and Ogawa M (1997) Neutrophil elastase inhibitor reduces neutrophil chemoattractant production after ischemia-reperfusion in rat liver. Gastroenterology 112:551-560. (Pubitemid 27078842)
259. Yamaguchi Y, Matsumura F, Liang J, Okabe K, Ohshiro H, Ishihara K, Matsuda T, Mori K, and Ogawa M (1999) Neutrophil elastase and oxygen radicals enhance monocyte chemoattractant protein- expression after ischemia/reperfusion in rat liver. Transplantation 68:1459-1468.
260. Yamamoto Y, Nakajima M, Yamazaki H, and Yokoi T (2001) Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 70:471-482. (Pubitemid 34017540)
261. Yee SB, Ganey PE, and Roth RA (2003a) The role of Kupffer cells and TNF-α in monocrotaline and bacterial lipopolysaccharide-induced liver injury. Toxicol Sci 71:124-132. (Pubitemid 36163712)
262. Yee SB, Hanumegowda UM, Hotchkiss JA, Ganey PE, and Roth RA (2003b) Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure. Toxicol Sci 72:43-56. (Pubitemid 36336433)
263. Yoshigae Y, Konno K, Takasaki W, and Ikeda T (2000) Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans. J Toxicol Sci 25:433-441. (Pubitemid 32055045)
264. Zimmerman HJ (1993) Hepatotoxicity. Dis Mon 39:675-787.
265. Zimmerman HJ (2000) Drug-induced liver disease. Clin Liver Dis 4:73-96, vi.
266. Zimmerman HJ (1999) Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, Lippincott Williams & Wilkins, Philadelphia.
267. Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, and Ganey PE (2009) Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci 108:184-193.
268. Zuurbier KW, Bakkenist AR, Fokkens RH, Nibbering NM, Wever R, and Muijsers AO (1990) Interaction of myeloperoxidase with diclofenac. Inhibition of the chlorinating activity of myeloperoxidase by diclofenac and oxidation of diclofenac to dihydroxyazobenzene by myeloperoxidase. Biochem Pharmacol 40:1801-1808. (Pubitemid 20337961)